Use of Risk Factors To Select Adjuvant Therapy Versus Surveillance for Testicular Nonseminoma and Seminoma Germ Cell Tumors
New risk factors associated with relapse of stage I testicular cancer have been identified. These new factors reflect the risk of recurrence much better than previous parameters and can be used to assess the possible effect of adjuvant chemotherapy.
Gespeichert in:
| Veröffentlicht in: | European urology focus 2024-05, Vol.10 (3), p.359-360 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 360 |
|---|---|
| container_issue | 3 |
| container_start_page | 359 |
| container_title | European urology focus |
| container_volume | 10 |
| creator | Daugaard, Gedske Lauritsen, Jakob Bandak, Mikkel Agerbæk, Mads Als, Anne B. Dysager, Lars Toft, Birgitte G. Engvad, Birte Berney, Daniel M. Wagner, Thomas |
| description | New risk factors associated with relapse of stage I testicular cancer have been identified. These new factors reflect the risk of recurrence much better than previous parameters and can be used to assess the possible effect of adjuvant chemotherapy. |
| doi_str_mv | 10.1016/j.euf.2024.06.001 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3068753616</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2405456924000907</els_id><sourcerecordid>3068753616</sourcerecordid><originalsourceid>FETCH-LOGICAL-c235t-27e9412f3c1517194189e448c33dbe93e7213ec36bf42ae30cc0d5e19b9c682e3</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMotlR_gBfJ0UvXfOxmd_FUil9QFHT1GtLsLKbubmqyKYh_3pRW8eRpZuCdd955EDqjJKGEistVAqFJGGFpQkRCCD1AY5aSbJpmojz804_QqfcrEhVZmvOCH6MRL4qcCk7H6OvFA7YNfjL-Hd8oPVjncWXxM7SgBzyrV2Gj-gFXb-DU-hO_gvPB4-fgNmDaVvUacGMdrsAPRodWOfxgew-d6W2nsOrraLUfbsF1eA5ti6vQxTsn6KhRrYfTfZ2gl5vran43XTze3s9ni6lmPBumLIcypazhmmY0p7EvSkjTQnNeL6HkkDPKQXOxbFKmgBOtSZ0BLZelFgUDPkEXO9-1sx8hBpWd8Rq26cEGLzkRRZ5xEYlMEN1JtbPeO2jk2plOuU9JidxilysZscstdkmEjFDjzvnePiw7qH83fiBHwdVOAPHJjQEnvTYQydXGRciytuYf-2-_DpML</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3068753616</pqid></control><display><type>article</type><title>Use of Risk Factors To Select Adjuvant Therapy Versus Surveillance for Testicular Nonseminoma and Seminoma Germ Cell Tumors</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Daugaard, Gedske ; Lauritsen, Jakob ; Bandak, Mikkel ; Agerbæk, Mads ; Als, Anne B. ; Dysager, Lars ; Toft, Birgitte G. ; Engvad, Birte ; Berney, Daniel M. ; Wagner, Thomas</creator><creatorcontrib>Daugaard, Gedske ; Lauritsen, Jakob ; Bandak, Mikkel ; Agerbæk, Mads ; Als, Anne B. ; Dysager, Lars ; Toft, Birgitte G. ; Engvad, Birte ; Berney, Daniel M. ; Wagner, Thomas</creatorcontrib><description>New risk factors associated with relapse of stage I testicular cancer have been identified. These new factors reflect the risk of recurrence much better than previous parameters and can be used to assess the possible effect of adjuvant chemotherapy.</description><identifier>ISSN: 2405-4569</identifier><identifier>EISSN: 2405-4569</identifier><identifier>DOI: 10.1016/j.euf.2024.06.001</identifier><identifier>PMID: 38871631</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Chemotherapy, Adjuvant ; Humans ; Male ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Neoplasms, Germ Cell and Embryonal - pathology ; Neoplasms, Germ Cell and Embryonal - therapy ; Risk Factors ; Seminoma - pathology ; Seminoma - therapy ; Testicular Neoplasms - pathology ; Testicular Neoplasms - therapy ; Watchful Waiting</subject><ispartof>European urology focus, 2024-05, Vol.10 (3), p.359-360</ispartof><rights>2024 European Association of Urology</rights><rights>Copyright © 2024 European Association of Urology. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c235t-27e9412f3c1517194189e448c33dbe93e7213ec36bf42ae30cc0d5e19b9c682e3</cites><orcidid>0000-0002-9618-9180</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38871631$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Daugaard, Gedske</creatorcontrib><creatorcontrib>Lauritsen, Jakob</creatorcontrib><creatorcontrib>Bandak, Mikkel</creatorcontrib><creatorcontrib>Agerbæk, Mads</creatorcontrib><creatorcontrib>Als, Anne B.</creatorcontrib><creatorcontrib>Dysager, Lars</creatorcontrib><creatorcontrib>Toft, Birgitte G.</creatorcontrib><creatorcontrib>Engvad, Birte</creatorcontrib><creatorcontrib>Berney, Daniel M.</creatorcontrib><creatorcontrib>Wagner, Thomas</creatorcontrib><title>Use of Risk Factors To Select Adjuvant Therapy Versus Surveillance for Testicular Nonseminoma and Seminoma Germ Cell Tumors</title><title>European urology focus</title><addtitle>Eur Urol Focus</addtitle><description>New risk factors associated with relapse of stage I testicular cancer have been identified. These new factors reflect the risk of recurrence much better than previous parameters and can be used to assess the possible effect of adjuvant chemotherapy.</description><subject>Chemotherapy, Adjuvant</subject><subject>Humans</subject><subject>Male</subject><subject>Neoplasm Recurrence, Local</subject><subject>Neoplasm Staging</subject><subject>Neoplasms, Germ Cell and Embryonal - pathology</subject><subject>Neoplasms, Germ Cell and Embryonal - therapy</subject><subject>Risk Factors</subject><subject>Seminoma - pathology</subject><subject>Seminoma - therapy</subject><subject>Testicular Neoplasms - pathology</subject><subject>Testicular Neoplasms - therapy</subject><subject>Watchful Waiting</subject><issn>2405-4569</issn><issn>2405-4569</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LAzEQhoMotlR_gBfJ0UvXfOxmd_FUil9QFHT1GtLsLKbubmqyKYh_3pRW8eRpZuCdd955EDqjJKGEistVAqFJGGFpQkRCCD1AY5aSbJpmojz804_QqfcrEhVZmvOCH6MRL4qcCk7H6OvFA7YNfjL-Hd8oPVjncWXxM7SgBzyrV2Gj-gFXb-DU-hO_gvPB4-fgNmDaVvUacGMdrsAPRodWOfxgew-d6W2nsOrraLUfbsF1eA5ti6vQxTsn6KhRrYfTfZ2gl5vran43XTze3s9ni6lmPBumLIcypazhmmY0p7EvSkjTQnNeL6HkkDPKQXOxbFKmgBOtSZ0BLZelFgUDPkEXO9-1sx8hBpWd8Rq26cEGLzkRRZ5xEYlMEN1JtbPeO2jk2plOuU9JidxilysZscstdkmEjFDjzvnePiw7qH83fiBHwdVOAPHJjQEnvTYQydXGRciytuYf-2-_DpML</recordid><startdate>202405</startdate><enddate>202405</enddate><creator>Daugaard, Gedske</creator><creator>Lauritsen, Jakob</creator><creator>Bandak, Mikkel</creator><creator>Agerbæk, Mads</creator><creator>Als, Anne B.</creator><creator>Dysager, Lars</creator><creator>Toft, Birgitte G.</creator><creator>Engvad, Birte</creator><creator>Berney, Daniel M.</creator><creator>Wagner, Thomas</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9618-9180</orcidid></search><sort><creationdate>202405</creationdate><title>Use of Risk Factors To Select Adjuvant Therapy Versus Surveillance for Testicular Nonseminoma and Seminoma Germ Cell Tumors</title><author>Daugaard, Gedske ; Lauritsen, Jakob ; Bandak, Mikkel ; Agerbæk, Mads ; Als, Anne B. ; Dysager, Lars ; Toft, Birgitte G. ; Engvad, Birte ; Berney, Daniel M. ; Wagner, Thomas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c235t-27e9412f3c1517194189e448c33dbe93e7213ec36bf42ae30cc0d5e19b9c682e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Chemotherapy, Adjuvant</topic><topic>Humans</topic><topic>Male</topic><topic>Neoplasm Recurrence, Local</topic><topic>Neoplasm Staging</topic><topic>Neoplasms, Germ Cell and Embryonal - pathology</topic><topic>Neoplasms, Germ Cell and Embryonal - therapy</topic><topic>Risk Factors</topic><topic>Seminoma - pathology</topic><topic>Seminoma - therapy</topic><topic>Testicular Neoplasms - pathology</topic><topic>Testicular Neoplasms - therapy</topic><topic>Watchful Waiting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Daugaard, Gedske</creatorcontrib><creatorcontrib>Lauritsen, Jakob</creatorcontrib><creatorcontrib>Bandak, Mikkel</creatorcontrib><creatorcontrib>Agerbæk, Mads</creatorcontrib><creatorcontrib>Als, Anne B.</creatorcontrib><creatorcontrib>Dysager, Lars</creatorcontrib><creatorcontrib>Toft, Birgitte G.</creatorcontrib><creatorcontrib>Engvad, Birte</creatorcontrib><creatorcontrib>Berney, Daniel M.</creatorcontrib><creatorcontrib>Wagner, Thomas</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European urology focus</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Daugaard, Gedske</au><au>Lauritsen, Jakob</au><au>Bandak, Mikkel</au><au>Agerbæk, Mads</au><au>Als, Anne B.</au><au>Dysager, Lars</au><au>Toft, Birgitte G.</au><au>Engvad, Birte</au><au>Berney, Daniel M.</au><au>Wagner, Thomas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of Risk Factors To Select Adjuvant Therapy Versus Surveillance for Testicular Nonseminoma and Seminoma Germ Cell Tumors</atitle><jtitle>European urology focus</jtitle><addtitle>Eur Urol Focus</addtitle><date>2024-05</date><risdate>2024</risdate><volume>10</volume><issue>3</issue><spage>359</spage><epage>360</epage><pages>359-360</pages><issn>2405-4569</issn><eissn>2405-4569</eissn><abstract>New risk factors associated with relapse of stage I testicular cancer have been identified. These new factors reflect the risk of recurrence much better than previous parameters and can be used to assess the possible effect of adjuvant chemotherapy.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>38871631</pmid><doi>10.1016/j.euf.2024.06.001</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0002-9618-9180</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2405-4569 |
| ispartof | European urology focus, 2024-05, Vol.10 (3), p.359-360 |
| issn | 2405-4569 2405-4569 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3068753616 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Chemotherapy, Adjuvant Humans Male Neoplasm Recurrence, Local Neoplasm Staging Neoplasms, Germ Cell and Embryonal - pathology Neoplasms, Germ Cell and Embryonal - therapy Risk Factors Seminoma - pathology Seminoma - therapy Testicular Neoplasms - pathology Testicular Neoplasms - therapy Watchful Waiting |
| title | Use of Risk Factors To Select Adjuvant Therapy Versus Surveillance for Testicular Nonseminoma and Seminoma Germ Cell Tumors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T13%3A49%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20Risk%20Factors%20To%20Select%20Adjuvant%20Therapy%20Versus%20Surveillance%20for%20Testicular%20Nonseminoma%20and%20Seminoma%20Germ%20Cell%20Tumors&rft.jtitle=European%20urology%20focus&rft.au=Daugaard,%20Gedske&rft.date=2024-05&rft.volume=10&rft.issue=3&rft.spage=359&rft.epage=360&rft.pages=359-360&rft.issn=2405-4569&rft.eissn=2405-4569&rft_id=info:doi/10.1016/j.euf.2024.06.001&rft_dat=%3Cproquest_cross%3E3068753616%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3068753616&rft_id=info:pmid/38871631&rft_els_id=S2405456924000907&rfr_iscdi=true |